-
Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China
•
Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration and license agreement with Shanghai-based Celest Therapeutics Co., Ltd. The partnership will see Celest manage a pilot clinical trial in mainland China for Senti’s SENTI-301A, an off-the-shelf CAR-NK cell therapy targeting GPC3-expressing tumors. Senti will…
-
Qingdao’s Raise Care Secures Over RMB 100 Million in Series B Financing Led by CITIC Capital
•
Qingdao-based Raise Care has reportedly secured upwards of RMB 100 million (USD 13.7 million) in a Series B financing round, according to recent reports. The round was led by CITIC Capital’s healthcare fund, with participation from CICC Capital, Jufeng S&T Venture Investment, and other investors. Company Background and FocusFounded in…
-
Novo Nordisk Reports 33% YOY Growth in Q3 2023 with Diabetes and Obesity Care Driving Sales
•
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has released its Q3 2023 earnings report, showcasing a 33% year-on-year (YOY) growth in constant exchange rates (CER) to DKK 166.4 billion (USD 23.7 billion) over the first nine months. The company identified diabetes care and obesity care as the key growth drivers,…
-
Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program
•
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third quarter of 2023, reporting a contraction of -41% year-on-year (YOY) in operational terms to USD 13.2 billion, excluding foreign currency fluctuations. The quarter was marked by a net loss of USD 2.38 billion, the company’s…
-
Daiichi Sankyo Reports 19.5% YOY Revenue Growth in First Half of Fiscal 2023
•
Japan’s Daiichi Sankyo (TYO: 4568) reported a robust 19.5% year-on-year (YOY) increase in revenue for the six months ended September 30, 2023, reaching JPY 726.3 billion (USD 4.8 billion), according to the company’s financial report published this week. This growth was driven by a combination of factors, including the depreciation…
-
GSK Reports Modest 2% YOY Growth in Q3 2023 Finances, Vaccines Unit Soars 24%
•
UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third quarter of 2023, showing mixed results over the first three quarters. The company experienced a modest 2% year-on-year (YOY) expansion, reaching GBP 22.3 billion (USD 27.7 billion) at constant exchange rates. Vaccines Unit and General…
-
We-Linking Secures Angel Financing for Implantable Brain Computer Interface Development
•
Shenzhen-based company We-Linking, a specialist in implantable brain computer interfaces (BCI), has reportedly raised tens of millions of renminbi in an angel financing round. The round was led by Gaorong Capital, with additional investments from Beijing Life Science Park Innovation Investment Fund, Qiji Investment, and existing investor CDH Investments. We-Linking’s…
-
ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development
•
ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100 million (USD 13.7 million) in a Series A financing round. The round was led by SDIC Venture Capital, with significant participation from Huangpu Pharmaceutical Fund and Yuanxi Haihe Fund. The funds will be instrumental in…
-
Bio-Techne Corporation Reports 2% YOY Revenue Growth in Q1 2024 Fiscal Report
•
US-based life sciences service provider Bio-Techne Corporation (NASDAQ: TECH) has released its Q1 report for the fiscal year 2024, which ended on September 30, 2023. The company reported a 2% year-on-year (YOY) increase in revenues, reaching USD 276.9 million. Segment Performance and Revenue BreakdownBio-Techne’s Protein Sciences segment contributed USD 204.7…
-
AnHeart Therapeutics Signs Exclusive License Deal with Nippon Kayaku for Taletrectinib
•
China-based AnHeart Therapeutics has announced the signing of an exclusive license deal with Japan-based biopharma Nippon Kayaku Co., Ltd. This strategic partnership grants Nippon Kayaku marketing and distribution rights for AnHeart’s leading pipeline candidate, taletrectinib, a next-generation ROS1 inhibitor. Taletrectinib: A Promising Treatment for ROS1-Positive NSCLCTaletrectinib is an oral, potent,…
-
Amgen Reports Q3 2023 Financials: 5% Growth Driven by Volume Expansion
•
Amgen (NASDAQ: AMGN) has released its Q3 2023 financial results, showcasing a 5% year-on-year (YOY) increase in global sales, reaching USD 6.5 billion. This growth comes despite a 3% decrease in net selling price, primarily fueled by an impressive 11% increase in volume. Notably, this marks the company’s fourth consecutive…
-
Danyang Huichuang Secures Over USD 13.7 Million in Series B Funding for fNIRS Development
•
Danyang Huichuang Medical Equipment Co., Ltd, a China-based specialist in functional near-infrared spectroscopy (fNIRS), has reportedly secured over RMB 100 million (USD 13.7 million) in a Series B financing round. The funding round was led by Zhongke Haichuang, with additional contributions from Addor Capital, and existing investors Tsingyua Capital and…
-
AbbVie’s Q3 2023 Report Shows 6.0% YOY Decline in Net Revenues
•
AbbVie (NYSE: ABBV) released its Q3 2023 financial report last week, revealing a 6.0% year-on-year (YOY) decline in net revenues for the first nine months of the year, amounting to USD 40.0 billion. The decrease was attributed to underperformance across most business areas, with the exception of neuroscience, which reported…
-
Dr. Reddy’s Laboratories Reports 9% YOY Revenue Growth in Q2 2024 Fiscal Year
•
India-based generics giant Dr. Reddy’s Laboratories Ltd (NYSE: RDY) has released its financial report for the Q2 2024 fiscal year ended September 30, 2023. The company reported consolidated revenues of USD 828 million for the quarter, marking a 9% year-on-year (YOY) increase. This growth was primarily driven by robust generic…
-
Sanofi SA Reports Q3 2023 Financials with Focus on R&D and Dupixent Growth
•
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) released its Q3 2023 financial results, reporting a net sales decrease of -4.1% year-on-year (YOY) but an increase of 3.2% in constant currency terms, reaching EUR 11.96 billion (USD 12.64 billion). Despite maintaining the forecast for 2023 earnings per share (EPS) growth, Sanofi…
-
BMS Revenue Slips Due to Revlimid Erosion: Q3 2023 Insights
•
Bristol Myers Squibb (BMS; NYSE: BMY) reported a 3% year-on-year (YOY) revenue decline, excluding foreign exchange impact, to USD 11.0 billion for Q3 2023, as detailed in the company’s recently released financial report. The downturn was primarily attributed to a significant 41% YOY drop in sales of the multiple myeloma…
-
Sonosemi Medical Secures Over USD 27.3 Million in Series B Funding for Vascular Intervention Devices
•
Sonosemi Medical Co., Ltd., a Shenzhen-based innovator in vascular graft intervention devices, has reportedly secured over RMB 200 million (USD 27.3 million) in a Series B financing round. The round was co-led by Yuexiu Industrial Investment Fund and CCB PE, with significant contributions from Tencent Investment, Eight Roads, and Alwin…
-
Novartis Q3 Earnings Reflect Strong Growth Post-Sandoz Spinoff
•
Novartis (NYSE: NVS) has released its Q3 2023 financial results, marking the first report since the company sharpened its focus on innovative medicines following the spinoff of Sandoz (SWX: SDZ) earlier this month. The financials reveal a robust performance with net sales reaching USD 34.0 billion for the first nine…
-
Leadinno Medical Valley Secures Series A+ Funding for Neuroregulation Device R&D
•
Leadinno Medical Valley, a Beijing-based innovator in pain management and neuroregulation devices, has reportedly secured over RMB 100 million (USD 15.7 million) in a Series A+ financing round. The funding, led by Dachen Caizhi Fortunevc with additional contributions from Wuxi Zhaoze Lifeng Investment, is earmarked for the research and development…
